PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-14.06%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$18.1M
(-9.1%)
Cap. Flow
+$21.8M
Cap. Flow
% of AUM
12.11%
Top 10 Holdings %
Top 10 Hldgs %
59.22%
Holding
45
New
6
Increased
14
Reduced
14
Closed
11
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.6
years
Top 20 Avg Time Held Equity + Options
0.6
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$12.1M |
| 2 |
United Therapeutics
UTHR
|
+$10M |
| 3 |
MeiraGTx Holdings
MGTX
|
+$7.87M |
| 4 |
R1 RCM Inc. Common Stock
RCM
|
+$4.82M |
| 5 |
Guardant Health
GH
|
+$3.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$5.29M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$4.96M |
| 3 |
Zimmer Biomet
ZBH
|
+$4.87M |
| 4 |
Q32 Bio
QTTB
|
+$4.07M |
| 5 |
Indaptus Therapeutics
INDP
|
+$3.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.43% |
| 2 | Industrials | 2.03% |
| 3 | Miscellaneous | 0.55% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TLGT
26
DELISTED
Teligent, Inc
TLGT
| $2.32M | 1.29% |
244,604
-52,168
| -18% | -$411K |
2018 Q1
6 quarters
|
|
|
CLVS
27
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.31M | 1.28% |
587,626
+137,626
| +31% | +$1.11M |
2018 Q4
3 quarters
|
|
28
Personalis
PSNL
$1.7B
| $1.69M | 0.94% |
115,214
+58,768
| +104% | +$1.11M |
2019 Q2
1 quarter
|
|
29
Cigna
CI
$76.6B
| $1.67M | 0.93% |
11,000
-20,227
| -65% | -$3.29M |
2018 Q1
6 quarters
|
|
30
DELISTED
Molecular Templates, Inc.
MTEM
| $1.47M | 0.82% |
14,866
+1,687
| +13% | +$157K |
2019 Q1
2 quarters
|
|
|
RETA
31
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $988K | 0.55% |
+12,300
| New | +$1.04M |
2019 Q3
0 quarters
|
|
|
UROV
32
DELISTED
Urovant Sciences Ltd.
UROV
| $972K | 0.54% |
102,657
-39,963
| -28% | -$347K |
2019 Q1
2 quarters
|
|
|
SRRA
33
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $924K | 0.51% |
59,168
-7,872
| -12% | -$151K |
2018 Q1
6 quarters
|
|
34
Tempest Therapeutics
TPST
$11M
| $370K | 0.21% |
267
-112
| -30% | -$181K |
2018 Q3
4 quarters
|
|
35
Everforth Inc
EFOR
$1.58B
| – | – |
-30,000
| Closed | -$1.82M | – |
|
36
Assembly Biosciences
ASMB
$414M
| – | – |
-16,667
| Closed | -$2.7M | – |
|
37
DELISTED
Cidara Therapeutics
CDTX
| – | – |
-17,948
| Closed | -$603K | – |
|
38
Evolus
EOLS
$481M
| – | – |
-112,590
| Closed | -$1.65M | – |
|
39
PUT
DELISTED
Exact Sciences
EXAS
| – | – |
-14,100
| Closed | -$1.66M | – |
|
|
40
Indaptus Therapeutics
INDP
$300M
| – | – |
-364
| Closed | -$3.54M | – |
|
41
DELISTED
Kezar Life Sciences
KZR
| – | – |
-3,422
| Closed | -$264K | – |
|
42
DELISTED
ModivCare
MODV
| – | – |
-14,677
| Closed | -$842K | – |
|
43
Neurogene
NGNE
$430M
| – | – |
-182
| Closed | -$9K | – |
|
44
DELISTED
NEVRO CORP.
NVRO
| – | – |
-11,000
| Closed | -$713K | – |
|
|
WCG
45
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-6,500
| Closed | -$1.85M | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2019 Portfolio in Review
As of Q3 2019, Prosight Management held 45 positions worth $180M, down 9.1% from $198M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Prosight Management deployed $21.8M of net new capital in Q3 2019, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was MeiraGTx Holdings: 338,096 shares worth $5.39M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $5.29M trimmed.
- Prosight Management's largest Q3 2019 buy was MeiraGTx Holdings: 338,096 shares worth $5.39M.
- Prosight Management added most to uniQure in Q3 2019, an estimated $12.1M increase.
- Prosight Management's biggest Q3 2019 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $5.29M.
- Prosight Management fully exited Indaptus Therapeutics in Q3 2019, selling an estimated $3.54M.
- Prosight Management's ten largest holdings make up 59% of its $180M portfolio in Q3 2019.
- Prosight Management opened 6 new positions and closed 11 in Q3 2019.
- Prosight Management's portfolio value fell 9.1% quarter-over-quarter to $180M.
Based on Prosight Management's 13F filing for Q3 2019, filed 14 Nov 2019.